A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors

被引：0
|
作者：
Ji, Dongmei
Weitao, Yao
Tong, Xiangmin
Zhang, Chenping
Wang, Feng
Chen, Zhendong
Zhou, Yuhong
Li, Zhendong
Deng, Yaotiao
Huang, Gang
Tao, Zhiwei
Zheng, Yulong
Wang, Gang
Liu, Guowen
Chen, Jing
Niu, Xiaohui
Yang, Jilong
Pang, Weijia
Zhao, Min
Hu, Xichun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Orthoped, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] ZheJiang Prov Peoples Hosp, Dept Hematol, Hangzhou, Peoples R China
[5] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Anhui Med Univ, Affiliated Hosp 2, Dept Oncol, Hefei, Peoples R China
[8] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[11] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Orthoped & Soft Tissue, Changsha, Peoples R China
[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Univ Sci & Technol China, Affiliated Hosp 1, Hefei, Peoples R China
[15] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China
[16] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[17] Beijing Jishuitan Hosp, Beijing, Peoples R China
[18] Beijing Jishuitan Hosp, Beijing, Peoples R China
[19] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[20] ImmVira Co Ltd, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
    Papadopoulos, K. P.
    Harb, W.
    Lu, N.
    Ma, X.
    He, Y.
    Yuan, L.
    Fu, M.
    Lin, Y.
    Xu, W.
    Wang, X.
    Wang, P.
    Xu, T.
    Dong, R.
    Gong, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 405 - 405
  • [32] Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
    Hidenori Mizugaki
    Noboru Yamamoto
    Haruyasu Murakami
    Hirotsugu Kenmotsu
    Yutaka Fujiwara
    Yoshimasa Ishida
    Tomohisa Kawakami
    Toshiaki Takahashi
    Investigational New Drugs, 2016, 34 : 596 - 603
  • [33] Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
    Mizugaki, Hidenori
    Yamamoto, Noboru
    Murakami, Haruyasu
    Kenmotsu, Hirotsugu
    Fujiwara, Yutaka
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 596 - 603
  • [34] Phase 1/2a study of BAL101553, a novel tumor checkpoint controller, administered as 48-h infusion in patients with advanced solid tumors
    Joerger, Markus
    Mark, Michael
    Stathis, Anastasios
    Hess, Dagmar
    Stuedeli, Silvia
    Berardi, Simona
    Kaindl, Thomas
    Larger, Patrice
    Von Moos, Roger
    Sessa, Cristiana
    SWISS MEDICAL WEEKLY, 2018, 148 : 18S - 18S
  • [35] A PHASE I, DOSE ESCALATION AND EXPANSION STUDY OF PT199, A NEXT GENERATION CD73 MONOCLONAL ANTIBODY, ADMINISTERED ALONE AND IN COMBINATION WITH A PD-1 INHIBITOR IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
    Melhem, Ramzi
    Wright, Harold
    Zou, Hui
    Ramos, Claudia
    Li, Jack
    Wang, Ming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A811 - A811
  • [36] PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: PART 1 RESULTS
    Friedman, Claire
    Carvajal, Richard
    Davar, Diwakar
    Castanon, Eduardo
    Ascierto, Paolo
    Calvo, Emiliano
    O'Hara, Mark
    Powell, Steven
    Shapira-Frommer, Ronnie
    Garralda, Elena
    Renouf, Daniel John
    Perets, Ruth
    Yunan, Mona
    Ravindran, Palanikumar
    Hammell, Amy
    O'Brien, Shaun
    Xu, Ke
    Wilson, Nicholas
    Jhatakia, Amy
    Mukhopadhyay, Anandaroop
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A620 - A621
  • [37] DESIGN AND RATIONALE OF A PHASE 1 STUDY EVALUATING AMG 256, A NOVEL, TARGETED, IL-21 RECEPTOR AGONIST AND ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Durm, Gregory
    Frentzas, Sophia
    Rasmussen, Erik
    Najmi, Saltanat
    Sadraei, Nooshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A254 - A254
  • [38] A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)
    Bendell, Johanna
    Rasco, Drew
    Park, Wungki
    Zhou, Lei
    Galkin, Anna
    Slee, Debbie
    Carter, Laura
    Nickle, David
    Tran, Rebecca
    Li, Jack
    Ferguson, Beatrice
    Dupont, Jakob
    Gupta, Vineet
    O'Reilly, Eileen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
    Xu, Jian-Ming
    Qin, Shukui
    Zhang, Yun
    Zhang, Yaoyue
    Jia, Ru
    Liu, Rongrui
    Zhang, Gairong
    Zhao, Chuanhua
    Lu, Ni
    Liu, Huilong
    Xu, Wenlian
    Fu, Meng
    Cao, Walt
    Lu, Haolan
    Liu, David
    Dong, Ruiping
    Wang, Xiaoxiao
    Wang, Pilin
    Xu, Ting
    Gong, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
    Ahnert, Jordi Rodon
    Taylor, Matthew H.
    O'Reilly, Eileen Mary
    Zhang, Jingsong
    Doebele, Robert Charles
    Ben, Yong
    Sharp, Leslie L.
    Boyle, William J.
    Chang, Cathy
    Frey, Gerhard
    Chen, Wei
    Melnick, Michael
    Short, Jay M.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345